证券代码：002980 证券简称：华盛昌 公告编号：2025-027 深圳市华盛昌科技实业股份有限公司 关于全资子公司与关联方共同投资设立合资公司 本次关联交易不构成《上市公司重大资产重组管理办法》规定的重大资产重 组，不构成重组上市，无需经过有关部门批准。 二、关联方的基本情况 （一）深圳市华眸企业管理合伙企业（有限合伙） 暨关联交易的公告 本公司及公司全体董事会成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、关联交易的基本情况 为加速推进深圳市华盛昌科技实业股份有限公司（以下简称"公司"）在人 工智能眼镜的战略布局，重点构建新一代专业领域测试测量仪器仪表应用新生态。 通过建立核心团队与企业发展成果深度绑定的长效激励机制，充分激发骨干员工 积极性，实现风险共担、利益共享，公司全资子公司深圳深度感测技术有限公司 （以下简称"深度感测"）拟与深圳市华眸企业管理合伙企业（有限合伙）（以 下简称"华眸企业"）、深圳市华境企业管理合伙企业（有限合伙）（以下简称 "华境企业"）共同投资设立深圳市深境智能技术有限公司（暂定名，最终名称 以工商注册为准），合资公司注册资本1,000万元。 ...

一、董事会会议召开情况 深圳市华盛昌科技实业股份有限公司（以下简称"公司"）第三届董事会2025 年第三次会议通知于2025年6月17日以邮件等方式发出，经全体董事确认，一致 同意豁免会议通知时间要求。会议于2025年6月17日10:00以通讯方式召开。会议 应出席董事8人，实际出席董事8人，均以通讯表决方式出席会议，会议由董事长 袁剑敏先生主持，公司部分高级管理人员列席了会议。本次会议的召开，符合《中 华人民共和国公司法》、《中华人民共和国证券法》的相关规定。 二、董事会会议审议情况 经与会董事充分讨论与表决，通过了以下议案： 1、审议通过了《关于全资子公司与关联方共同投资设立合资公司暨关联交 易的议案》 证券代码：002980 证券简称：华盛昌 公告编号：2025-026 深圳市华盛昌科技实业股份有限公司 第三届董事会 2025 年第三次会议决议公告 本公司及公司全体董事会成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 公司实际控制人、董事长、总经理袁剑敏先生为华眸企业、华境企业执行事 务合伙人，公司董事、副总经理胡建云先生为华眸企业合伙人。关联董事袁剑敏 先生、胡建云先生 ...

Group 1 - The core point of the article is that Huashengchang plans to accelerate its AI glasses strategy by establishing a joint venture through its wholly-owned subsidiary [1] - The joint venture, Shenzhen Shenjing Intelligent Technology Co., Ltd., will have a registered capital of 10 million yuan, with Huashengchang contributing 7 million yuan, holding a 70% stake [1] - The collaboration aims to build a new ecosystem for the application of next-generation professional testing and measurement instruments in the field of artificial intelligence [1]

Core Viewpoint - The company is accelerating its strategic layout in artificial intelligence glasses by establishing a joint venture focused on smart technology [1] Group 1: Investment Details - The wholly-owned subsidiary Shenzhen Deep Sensing Technology Co., Ltd. plans to jointly invest with Shenzhen Huamou Enterprise Management Partnership and Shenzhen Huajing Enterprise Management Partnership to establish Shenzhen Deep Boundary Intelligent Technology Co., Ltd. [1] - The registered capital of the joint venture is 10 million yuan, with Deep Sensing contributing 7 million yuan, holding a 70% stake [1] Group 2: Strategic Objectives - The investment aims to create a long-term incentive mechanism that closely binds the core team with the company's development outcomes, enhancing employee motivation [1] - The initiative is designed to achieve risk-sharing and benefit-sharing among key employees [1]

Group 1 - The nuclear pollution prevention sector has seen significant gains, with companies like China General Nuclear Power Technology (000881) reaching the daily limit increase [1] - Other companies in the sector, such as Jieqiang Equipment (300875), Beihua Co., Ltd. (002246), and Huashengchang (002980), also experienced a surge, hitting their daily limit [1] - Zhongjin Irradiation (300962) rose nearly 19%, indicating strong market interest in nuclear-related stocks [1] Group 2 - Additional companies like China Electric Environmental Protection (300172), Rongji Software (002474), and others also followed the upward trend, reflecting a broader market movement in this sector [1] - The overall positive sentiment in the nuclear pollution prevention sector suggests potential investment opportunities as more companies join the rally [1]

Core Viewpoint - The report details the shareholding changes of Shenzhen Huashengchang Technology Industrial Co., Ltd., specifically the reduction of shares held by major shareholders, including Yuan Jianmin and associated enterprises, to meet employee funding needs and incentivize key staff [1][5][6]. Group 1: Shareholding Changes - As of June 10, 2025, the total shares held by the information disclosure obligors decreased from 113,910,020 shares (60.22% of total shares) to 113,484,720 shares (60.00% of total shares) following a reduction of 425,300 shares [7][8]. - The reduction was executed through block trading, with specific transactions occurring on June 9 and June 10, 2025, at prices of 17.47 and 17.64 RMB per share, respectively [7][8]. Group 2: Purpose of Shareholding Change - The primary purpose of this shareholding change is to satisfy the personal funding needs of certain employees and to motivate key personnel to create value for the company [6][5]. Group 3: Future Plans - The information disclosure obligors have indicated the possibility of further increasing or decreasing their shareholdings within the next 12 months, adhering to relevant legal and regulatory requirements [6][9].

证券代码：002980 证券简称：华盛昌 公告编号：2025-025 深圳市华盛昌科技实业股份有限公司 关于股东权益变动触及 5%整数倍的提示性公告 一、本次权益变动基本情况 深圳市华盛昌科技实业股份有限公司（以下简称"公司"）于 2025 年 6 月 及 5%整数倍的告知函》及附件《简式权益变动报告书》，华聚企业、华航企业 售条件流通股 425,300 股，占公司总股本的 0.22%。截至本报告披露日，袁剑敏 先生、华 聚企业、 华 航企业 合 计持有公 司 股份数由 113,910,020 股减少至 会《上市公司收购管理办法》、《证券期货法律适用意见第 19 号—— <上市公司> 收购管理办法>第十三条、第十四条的适用意见》的规定，本次权益变动后导致 袁剑敏先生、华聚企业、华航企业持有股份占公司已发行股份的比例触及 5%的 整数倍。具体权益变动情况如下： 基本情况 | | 深圳市南山区西丽白芒 | | --- | --- | | 深圳市华盛昌科技实业 | 上市公司所在 | | 上市公司名称 | 松白公路百旺信工业区 | | 股份有限公司 | 地 | | | 五区 19 栋 | | 股票简称 华盛昌 | 股 ...

证券代码：002980 证券简称：华盛昌 公告编号：2025-025 深圳市华盛昌科技实业股份有限公司 关于股东权益变动触及 5%整数倍的提示性公告 2、本次权益变动前，袁剑敏先生、华聚企业、华航企业合计持股113,910,020 股，占公司总股本的60.22%（占公司剔除回购专用账户股份数量后总股本的 60.38%）；本次权益变动后，袁剑敏先生、华聚企业、华航企业合计持股113,484,720 股，占公司总股本的60.00%（占公司剔除回购专用账户股份数量后总股本的 60.15%）。 3、本次权益变动不会导致公司控股股东、实际控制人发生变化，不会对公 司治理结构及未来持续经营产生重大影响。 一、本次权益变动基本情况 深圳市华盛昌科技实业股份有限公司（以下简称"公司"）于 2025 年 6 月 10 日收到股东袁剑敏先生、华聚企业、华航企业出具的《关于减持华盛昌股份触 及 5%整数倍的告知函》及附件《简式权益变动报告书》，华聚企业、华航企业 2025 年 6 月 9 日至 2025 年 6 月 10 日通过大宗交易方式减持其持有的公司无限 售条件流通股 425,300 股，占公司总股本的 0.22%。截至本报 ...

深圳市华盛昌科技实业股份有限公司 简式权益变动报告书 上市公司名称：深圳市华盛昌科技实业股份有限公司 股票上市地点：深圳证券交易所 股票简称：华盛昌 股票代码：002980 信息披露义务人（一）：袁剑敏 住所：深圳市福田区******* 通讯地址：深圳市福田区******* 信息披露义务人（二）：东台华聚企业管理合伙企业（有限合伙） 住所：东台经济开发区中欧产业园内 通讯地址：东台经济开发区中欧产业园内 信息披露义务人（三）：东台华航企业管理咨询合伙企业（有限合伙） 住所：东台经济开发区中欧产业园内 通讯地址：东台经济开发区中欧产业园内 股份变动性质：减少（减持） 签署日期：2025年6月10日 1 信息披露义务人声明 一、本报告系依据《中华人民共和国证券法》、《上市公司收购管理办法》、 《公开发行证券的公司信息披露内容与格式准则第15号——权益变动报告书》及 相关法律法规及规范性文件编写。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定， 本报告书已全面披露信息披露义务人在深圳市华盛昌科技实业股份有限公司中 拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，上述信息披 ...

Core Viewpoint - The launch of the HX-660 dual-level non-invasive ventilator by Huashengchang aims to address the growing demand for home medical devices, particularly for individuals suffering from sleep apnea and hypoventilation syndrome, leveraging advanced smart technology to enhance respiratory function and improve sleep quality [1][3]. Product Features - The HX-660 ventilator is designed with intelligent dual-pressure adjustment technology, which controls and regulates physiological breathing, making it suitable for complex respiratory issues [1][3]. - It includes built-in data tracking capabilities, allowing users to monitor sleep quality and automatically switch between various smart modes to optimize pressure support in real-time [1][5]. - The device features multiple sensors for dynamic pressure adjustment, real-time leak detection, and pressure compensation, enhancing user comfort [5]. Market Potential - The global home non-invasive ventilator market is projected to reach $5.577 billion by 2025, with a compound annual growth rate (CAGR) of 15.5% from 2020 to 2025 [3]. - The Chinese market for home non-invasive ventilators is expected to grow to 3.33 billion yuan by 2025, with a CAGR of 22.0% from 2021 to 2025, indicating a faster growth rate than the global market [3]. - Approximately 176 million people in China suffer from obstructive sleep apnea, presenting a significant opportunity for home ventilators, which currently have a penetration rate of less than 1% [3]. Strategic Positioning - Huashengchang is actively expanding its "AI + Medical" product line, capitalizing on the rapid growth of the home medical device market in China, which is expected to exceed 300 billion yuan by 2026 [7]. - The company utilizes AI technology to enhance the sensitivity and accuracy of measuring key physiological parameters, enabling adaptive adjustments based on user characteristics [8]. - The integration of AI allows for the generation of multi-dimensional analysis reports, transforming raw data into visual trend maps and warning indicators, thus promoting proactive health management [8].